Biosimilars industry calls for policy change in Europe

Hailing the benefits of 15 years of biosimilar prescribing in Europe, The Biosimilar Medicines Group has called on the European Medicines Agency to take stronger action to widen access to this type of medicine.

The organization is part of the broader Medicines for Europe trade body, which represents leading companies developing and distributing biosimilars and generics in the region.

In a statement, the group noted that biosimilars have “paved the way for millions of patients to access life changing therapies,” enabling healthcare systems to save an estimated 18 billion euros ($20 billion) in the process.